Novartis highlights positive Phase II psoriasis data; Meeker named Genzyme CEO; Corden axes 60 from former Roche facility;

@FierceBiotech: $5M for web-based clinical tech firm goBalto. Item | Follow @FierceBiotech

@JohnCFierce: Cubist ($CBST) has been on a roll recently, hitting a 52-wk high friday. Interested to see the market reaction this a.m. | Follow @JohnCFierce

@RyanMFierce: No surprise to see David Meeker tapped as Genzyme's CEO. The COO can take reins without the co skipping a beat. Hope it's the right beat. | Follow @RyanMFierce

@MaureenFierce: NIH doesn't want to predict the future of medicine, just enable it. - Collins, #AAPS2011 | Follow @MaureenFierce

> Novartis says a slate of mid-stage studies of AIN457 (secukinumab) proved promising in treating symptoms of moderate to severe plaque psoriasis. Story

> David Meeker, who heads Genzyme's rare disease division, has been named CEO of the Boston biotech. Release

> Two months after it bought Roche's site in Boulder, CO, Corden Pharma says it will lay off 60 workers. Report

> Australia's Pharmaxis has won EU approval for Bronchitol, a new drug for cystic fibrosis. The treatment is being considered by the FDA. Story

> Vertex Pharmaceuticals has launched a Phase IIIb study called CONCISE that will evaluate the potential shortening treatment with Incivek (telaprevir) combination therapy to 12 weeks in people with genotype 1 chronic hepatitis C who have the ‘CC' variation near the IL28B gene. Release

> The FDA has approved Lundbeck's epilepsy drug Onfi. Report

> Silence Therapeutics will collaborate with Mirna Therapeutics on new delivery technology for Mirna's RNAi programs. Release

Pharma News

@FiercePharma: 10 largest U.S. patent losses. Feature | Follow @FiercePharma

> Abbott execs predict big growth for pharma spinoff. Story

> Chinese dairy eyes bid for Pfizer nutritionals. Article

> Vertex tests shorter Incivek therapy in patient subset. Item

> Korean FTC fines Glaxo, Dong-A in generic Zofran delay. More

> Abbott's off-label deal said to be $800M civil, $500M criminal. Article

Medical Devices News

> Zimmer, Benvenue Medical conclude distribution deal. Piece

> Nobel Biocare rises on buyout talks. Report

> Catheter maker VistaMed to create 79 jobs. More

> Cambridge Heart details results from Cardiac Science promotion. Article

> Alere meets conditions for Axis-Shield takeover. Article

> VisionGate raises $2M, concludes agreement. News

Biotech IT News

> Big prize in genomics might reside in bioinformatics. More

> Microsoft donates open source bio project to Outercurve. Story

> MIT cell biologist named head of $2B NIH unit. Report

> Indiana U zeros in on supercomputing for new genome analysis center. News

> $5M for web-based clinical tech firm goBalto. Item

> GenoLogics taps sequencing powerhouse Illumina in $8M round. Piece

And Finally... A new study from the NYU Cancer Institute suggests that inhibiting the CK1 enzyme "may be a new therapeutic target for the treatment of cancer cells formed as a result of a malfunction in the cell's mTOR signaling pathway." Release